Dr. Bendell on the Next Steps Following Progression on Immunotherapy in MSI-H CRC

Video

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the next steps following progression on checkpoint inhibitors in microsatellite instability-high (MSI-H) colorectal cancer (CRC).

For patients with MSI-H disease, they can still have the general standard chemotherapies that are still available to them, as well as targeted agents following progression on checkpoint inhibitor therapy, explains Bendell.

If a patient progresses on the checkpoint inhibitor, they could potentially go on to regorafenib (Stivarga), TAS-102 (Lonsurf), or a clinical trial. According to Bendell, there are many clinical trials that are looking at combinations for patients who have progressive disease following single-agent immunotherapies.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD